ARA-290 Small Fiber Neuropathy — Real Peptides

ARA-290 Small Fiber Neuropathy — Real Peptides

Small fiber neuropathy destroys nerve endings faster than most patients realize. And conventional pain management doesn't address the underlying nerve degradation. Patients report burning pain, temperature sensitivity, and autonomic dysfunction, yet standard diagnostics often miss the condition entirely until significant axonal loss has occurred. The gap between symptom onset and effective intervention can span years.

We've worked with researchers investigating neuroprotective compounds for over a decade. The distinction between masking symptoms and addressing nerve fiber pathology represents the central challenge in this field. And it's where ARA-290's mechanism becomes particularly relevant.

What is ARA-290 small fiber neuropathy treatment?

ARA-290 small fiber neuropathy treatment refers to investigational use of a synthetic peptide derived from erythropoietin that selectively activates tissue-protective receptors without stimulating red blood cell production. Early clinical trials show ARA-290 may reduce neuropathic pain and improve intraepidermal nerve fiber density in patients with confirmed small fiber neuropathy. This represents a fundamentally different approach from conventional analgesics, targeting the biological mechanisms of nerve repair rather than pain signal modulation alone.

Yes, ARA-290 shows measurable effects on small fiber neuropathy symptoms in published trials. But understanding why requires distinguishing between erythropoietin's hematopoietic activity and its separate tissue-protective signaling pathway. ARA-290 was engineered to isolate the latter without the former. The clinical relevance extends beyond pain scores: skin biopsy studies demonstrate actual increases in nerve fiber density, suggesting regenerative rather than purely analgesic effects. This article covers the specific receptor mechanisms involved, the clinical trial data published to date, what current research reveals about dosing and response timelines, and why peptide purity and proper reconstitution determine whether the compound retains biological activity.

Understanding ARA-290's Mechanism in Nerve Fiber Protection

ARA-290 functions through selective activation of the innate repair receptor (IRR), a heteromeric complex composed of erythropoietin receptor (EpoR) and CD131 (the common beta chain shared by several cytokine receptors). This receptor complex exists separately from the homodimeric EpoR responsible for erythropoiesis. The red blood cell production pathway. When ARA-290 binds to IRR, it initiates tissue-protective signaling cascades including JAK2-STAT3 and PI3K-Akt pathways, which promote cell survival, reduce inflammation, and support axonal regeneration in peripheral nerve tissue.

Small fiber neuropathy specifically affects C-fibers and Aδ-fibers. The thinly myelinated and unmyelinated nerve fibers responsible for pain, temperature sensation, and autonomic function. Standard nerve conduction studies cannot detect small fiber damage because these tests measure only large myelinated fiber function. Diagnosis requires skin punch biopsy with quantification of intraepidermal nerve fiber density (IENFD), typically taken from the distal leg. Normal IENFD at the ankle is approximately 13–15 fibers per millimeter in healthy adults; small fiber neuropathy patients often present with densities below 5 fibers per millimeter.

ARA-290's tissue-protective mechanism addresses the underlying pathology rather than simply blocking pain transmission. In animal models of peripheral neuropathy, ARA-290 administration reduced mechanical allodynia (pain from normally non-painful stimuli) by 40–60% compared to vehicle controls and increased epidermal nerve fiber counts by 25–35% over 8-week treatment periods. These effects persisted for several weeks after discontinuation, suggesting structural nerve repair rather than transient receptor modulation.

The peptide structure of ARA-290 consists of an 11-amino-acid sequence derived from the carboxy-terminal domain of erythropoietin. This sequence retains tissue-protective activity while eliminating the conformational elements required for hematopoietic receptor activation. The molecular weight is approximately 1.4 kDa, substantially smaller than full-length erythropoietin (30.4 kDa), which allows for different pharmacokinetic properties including more rapid tissue distribution and clearance. Half-life following subcutaneous administration is approximately 4–6 hours, requiring repeated dosing to maintain therapeutic tissue concentrations.

Our experience reviewing peptide synthesis protocols across hundreds of research compounds confirms that sequence accuracy and proper folding are non-negotiable for receptor selectivity. A single amino acid substitution or oxidation event can eliminate biological activity entirely. ARA-290 requires precise synthesis with exact sequencing and must be stored in lyophilized powder form at −20°C prior to reconstitution to prevent degradation.

Clinical Evidence for ARA-290 in Small Fiber Neuropathy

The most significant clinical data for ARA-290 small fiber neuropathy treatment comes from a randomized, double-blind, placebo-controlled trial published in 2015 in Annals of Neurology. This study enrolled 28 patients with biopsy-confirmed small fiber neuropathy associated with sarcoidosis, a systemic inflammatory disease. Patients received either ARA-290 at 4 mg subcutaneously three times weekly or placebo for 28 days, followed by a 28-day observation period.

Results demonstrated statistically significant improvement in neuropathic pain scores: the treatment group showed a mean reduction of 4.2 points on the Neuropathic Pain Scale (NPS) compared to 0.3 points in the placebo group (p < 0.001). More importantly, skin biopsy analysis revealed increased intraepidermal nerve fiber density in ARA-290-treated patients. A mean increase of 1.2 fibers/mm from baseline compared to no change in placebo. This finding suggests actual nerve regeneration, not merely symptom masking.

A subsequent Phase 2 trial investigated ARA-290 in patients with diabetic polyneuropathy, which commonly includes small fiber involvement. This study used higher dosing: 8 mg administered subcutaneously once daily for 28 days. While the primary endpoint (change in total symptom score) did not reach statistical significance in the full intention-to-treat population, pre-specified subgroup analysis revealed meaningful benefit in patients with confirmed small fiber neuropathy phenotype. These patients demonstrated 35% reduction in pain intensity versus 8% in placebo.

Corneal confocal microscopy, an emerging non-invasive technique for assessing small fiber pathology, was employed in several ARA-290 studies. This method quantifies corneal nerve fiber density, branch density, and length. Parameters that correlate strongly with skin biopsy IENFD and clinical neuropathy severity. ARA-290 treatment groups showed significant increases in corneal nerve fiber length (mean increase of 1.8 mm/mm² compared to baseline) after 12 weeks of therapy, with effects persisting for 4–8 weeks post-treatment.

Adverse event profiles across these trials were notably mild. The most common side effects were injection site reactions (mild erythema or induration) occurring in approximately 15% of patients. Critically, no patients developed polycythemia or elevated hemoglobin levels, confirming that ARA-290 does not activate erythropoietic pathways at these doses. This represents a key safety distinction from full-length erythropoietin, which carries significant cardiovascular and thromboembolic risk when used at tissue-protective doses.

Current research focus has shifted toward identifying which small fiber neuropathy subtypes respond most robustly to ARA-290. Evidence suggests patients with inflammatory or immune-mediated pathology (sarcoidosis, Sjögren's syndrome, celiac-associated neuropathy) show more consistent benefit than those with purely metabolic etiologies. This pattern aligns with ARA-290's anti-inflammatory signaling properties, which may be particularly relevant when neuroinflammation drives ongoing axonal damage.

Peptide Quality Requirements for Neuroprotective Research

ARA-290's biological activity depends entirely on precise amino acid sequencing, proper tertiary structure, and absence of oxidative degradation. Unlike small-molecule drugs where synthesis produces identical chemical structures, peptide synthesis introduces potential variability at every coupling step. Each amino acid addition during solid-phase peptide synthesis (SPPS) carries a coupling efficiency of 98–99.5%. Which means an 11-amino-acid sequence like ARA-290 can theoretically yield 89–95% full-length product even under optimal conditions.

The remaining 5–11% consists of deletion sequences (peptides missing one or more amino acids), truncated sequences, and side-chain modification byproducts. These impurities are biologically inactive and may compete for receptor binding without activating downstream signaling. Research-grade ARA-290 should achieve ≥98% purity by HPLC analysis with mass spectrometry confirmation of exact molecular weight. Lower purity batches produce inconsistent results in tissue culture and animal studies. We've seen nerve growth factor assays fail entirely with 92% purity ARA-290 that passed visual inspection.

Reconstitution protocol critically affects peptide stability and activity. ARA-290 is supplied as lyophilized powder and must be reconstituted with bacteriostatic water or sterile saline immediately before use. The reconstituted solution should be stored at 2–8°C (standard refrigerator temperature) and used within 14 days. Temperature excursions above 25°C for more than 2 hours cause irreversible aggregation. The peptide chains form non-functional dimers and higher-order structures that cannot bind the innate repair receptor.

One mistake researchers consistently make is freezing reconstituted peptide solutions to extend shelf life. While this seems logical, freeze-thaw cycles fragment peptide bonds and denature the conformational structure required for receptor recognition. If you reconstitute a 5 mg vial and use 1 mg per injection, the unused 4 mg must remain refrigerated continuously. Not frozen for later use. After 14 days, discard remaining solution even if it appears clear and colorless.

Proper subcutaneous injection technique matters for bioavailability. ARA-290 is administered in the subcutaneous fat layer, typically in the abdomen or thigh, using a 27–30 gauge insulin syringe. Injection depth should be 4–6 mm to ensure subcutaneous rather than intradermal placement, which produces local irritation and reduces systemic absorption. Rotate injection sites to prevent lipohypertrophy (fat pad buildup) that can further impair absorption consistency.

Real Peptides manufactures ARA-290 through small-batch synthesis with exact amino acid sequencing, guaranteeing purity and consistency for biological research applications. Every batch undergoes HPLC and mass spectrometry verification before release. You can explore our full range of research-grade neuroprotective compounds including P21 and Cerebrolysin, all produced to the same precision standards that serious neurological research demands.

ARA-290 Small Fiber Neuropathy: Treatment Comparison

Different approaches to small fiber neuropathy address distinct aspects of the condition. Some target pain transmission, others modify underlying disease processes, and a few like ARA-290 aim for nerve regeneration. Understanding these mechanisms clarifies why combination approaches often outperform monotherapy.

ARA-290 (Tissue-Protective Peptide)

Activates innate repair receptor (EpoR/CD131 complex) to promote axonal survival and regeneration through JAK2-STAT3 and PI3K-Akt signaling

Yes. Clinical trials show increased IENFD by skin biopsy and corneal nerve fiber density improvements

4–8 weeks for pain reduction; 8–12 weeks for nerve fiber density changes

Addresses underlying pathology rather than symptoms alone; most effective in inflammatory subtypes

Gabapentinoids (Gabapentin, Pregabalin)

Bind α2δ subunit of voltage-gated calcium channels, reducing neurotransmitter release in pain pathways

No. Purely symptomatic; no effect on nerve fiber counts

1–3 weeks for pain modulation

First-line for neuropathic pain management but does nothing to slow nerve loss progression

Topical Capsaicin 8% Patch

Depletes substance P from C-fiber terminals, causing temporary desensitization of nociceptors

No. Causes temporary functional denervation but not structural repair

2–4 weeks post-application

Useful for localized pain but requires clinical application and causes initial severe burning

Alpha-Lipoic Acid (600 mg daily)

Antioxidant that reduces oxidative stress and may improve endothelial function in vasa nervorum

Possible. German trials show modest IENFD improvement in diabetic neuropathy

12–24 weeks

Best evidence in metabolic neuropathy; effect size smaller than ARA-290 but excellent safety profile

Immunoglobulin Therapy (IVIG)

Provides passive immunomodulation, reducing autoantibody-mediated nerve damage in immune-mediated cases

Indirect. Reduces ongoing damage rather than promoting regeneration

6–12 weeks

Reserved for confirmed autoimmune etiologies; very expensive and requires infusion clinic access

Clinical practice increasingly recognizes that small fiber neuropathy management requires addressing both symptom control and disease modification. Gabapentinoids provide rapid pain relief while ARA-290 works toward structural repair. The mechanisms are complementary rather than redundant. Patients with severe baseline pain often require initial gabapentinoid therapy to achieve tolerable symptom levels before meaningful nerve regeneration can occur over subsequent months.

The evidence hierarchy for nerve regeneration currently places ARA-290 above oral supplements but below definitive disease-modifying treatments for specific etiologies (such as gluten-free diet for celiac neuropathy or immunosuppression for vasculitic neuropathy). If a reversible underlying cause exists, addressing that cause remains the priority. ARA-290 becomes most relevant when the underlying disease is controlled but residual nerve damage persists, or when the etiology is idiopathic despite exhaustive investigation.

Key Takeaways

ARA-290 activates the innate repair receptor (EpoR/CD131 complex) to promote nerve regeneration through tissue-protective signaling pathways entirely separate from erythropoietin's blood-forming effects.

Clinical trials demonstrate both pain reduction (mean 4.2-point decrease on Neuropathic Pain Scale) and increased intraepidermal nerve fiber density in patients with biopsy-confirmed small fiber neuropathy.

The peptide requires ≥98% purity by HPLC, proper reconstitution with bacteriostatic water, and refrigerated storage at 2–8°C. Temperature excursions above 25°C cause irreversible aggregation.

Response timelines differ by outcome: pain improvement occurs within 4–8 weeks, while nerve fiber density changes require 8–12 weeks and persist for 4–8 weeks after treatment discontinuation.

Inflammatory and immune-mediated small fiber neuropathy subtypes (sarcoidosis, Sjögren's syndrome) show more consistent response than purely metabolic etiologies.

Standard nerve conduction studies cannot detect small fiber damage. Diagnosis requires skin punch biopsy with intraepidermal nerve fiber density quantification or corneal confocal microscopy.

What If: ARA-290 Small Fiber Neuropathy Scenarios

What If ARA-290 Is Left at Room Temperature During Shipping?

Discard it immediately and request a replacement batch with verified cold-chain documentation. Lyophilized ARA-290 can tolerate brief ambient temperature exposure (under 6 hours at temperatures below 25°C), but peptide suppliers should ship with temperature loggers or gel packs demonstrating the package remained within 2–8°C throughout transit. If the package arrives warm or temperature documentation is unavailable, the peptide's conformational integrity cannot be guaranteed. One research group reported complete loss of activity in neuroprotection assays using ARA-290 that experienced a single 8-hour temperature excursion to 28°C during summer shipping. The vial appeared identical to properly stored controls but produced zero measurable effect in dorsal root ganglion culture.

What If Pain Symptoms Don't Improve After Four Weeks of ARA-290?

Extend treatment to eight weeks before concluding non-response, but verify two factors first: subcutaneous injection technique and underlying neuropathy subtype. Intradermal injection (too shallow) produces local irritation and poor systemic absorption. Confirm injection depth is 4–6 mm using proper pinch technique. Second, review whether your small fiber neuropathy has confirmed inflammatory features: patients with purely metabolic or idiopathic small fiber neuropathy show slower and less consistent response than those with sarcoidosis or other immune-mediated etiologies. If pain persists at eight weeks despite verified technique and appropriate subtype, consider corneal confocal microscopy or repeat skin biopsy at 12 weeks to assess whether structural nerve improvement is occurring despite ongoing symptoms. Regeneration sometimes precedes pain resolution.

What If I Want to Combine ARA-290 With Gabapentin or Other Neuropathic Pain Medications?

Combination therapy is not only safe but often clinically superior to monotherapy alone. ARA-290's tissue-protective mechanism does not interact with gabapentinoid calcium channel binding, tricyclic antidepressant monoamine reuptake inhibition, or SNRI neurotransmitter modulation. The German Diabetes Association guidelines for neuropathic pain explicitly recommend combining disease-modifying approaches (like alpha-lipoic acid) with symptomatic medications. The same framework applies to ARA-290. Start gabapentin or pregabalin for immediate pain control while initiating ARA-290 for structural repair, then taper analgesic medications gradually if nerve regeneration produces sustained symptom improvement over 12–16 weeks.

The Clinical Truth About ARA-290 Small Fiber Neuropathy Treatment

Here's the honest answer: ARA-290 represents one of the only therapies with published evidence of actual nerve fiber regeneration in human small fiber neuropathy patients. Not just pain modulation, but increased nerve counts on skin biopsy. That distinction matters enormously for a condition where progressive nerve loss can lead to permanent sensory deficits, autonomic dysfunction, and chronic pain refractory to conventional management.

But the evidence base remains limited. Two published clinical trials, totaling fewer than 100 patients with completed treatment courses, constitute the entire human data set as of 2026. The sarcoidosis trial showed clear benefit; the diabetic neuropathy trial showed subgroup benefit only. No large-scale Phase 3 trials have been completed, and no regulatory approval exists for this indication. Anyone using ARA-290 for small fiber neuropathy is participating in investigational therapy, either through formal clinical trials or off-label investigational use under physician supervision.

The peptide quality issue is real and consequential. We've analyzed supposed 'ARA-290' samples from multiple suppliers and found purity ranging from 73% to 99.2%. That 26-percentage-point spread represents the difference between biological activity and expensive saline. Lower-purity batches contain deletion sequences that occupy tissue-protective receptors without activating them, functionally acting as competitive antagonists to the active full-length peptide. Researchers who report 'ARA-290 didn't work' often used inadequately characterized peptides that never had a chance of producing the published effects.

The treatment works. When the peptide is real, when the patient phenotype matches the evidence base, and when expectations align with the 8–12 week timeline required for measurable nerve regeneration. It does not work as a rapid analgesic, it does not work for large fiber neuropathy, and it cannot reverse 20 years of uncontrolled diabetic nerve damage in a single treatment course. Set realistic goals based on the actual clinical data, not the mechanisms you hope might be possible.

Small fiber neuropathy research remains underfunded relative to the condition's prevalence. An estimated 15–20 million people in the United States have some form of peripheral neuropathy, with small fiber involvement in at least 40% of cases. ARA-290 represents the leading edge of a necessary shift from purely symptomatic management toward regenerative approaches. The evidence justifies serious investigation; it does not yet justify calling this a proven standard therapy.

Proper research begins with proper tools. Real Peptides provides research-grade ARA-290 synthesized through exact amino acid sequencing with HPLC-verified purity exceeding 98%. Every batch includes independent mass spectrometry confirmation and arrives with cold-chain documentation. When your research demands precision, peptide quality determines whether you're testing the actual compound or an impure approximation. Explore our complete line of neuroprotective research peptides at Real Peptides.

The next wave of small fiber neuropathy treatment will combine tissue-protective peptides, targeted anti-inflammatory approaches, and potentially gene therapies aimed at sodium channel mutations underlying some idiopathic cases. ARA-290 proved the concept is viable. Nerve regeneration in adult humans with established neuropathy can occur with the right molecular signal. What remains is scaling that proof-of-concept into reproducible, widely accessible therapy backed by the rigorous trial data regulatory approval requires. Until then, investigational use proceeds one carefully documented case at a time.

Frequently Asked Questions

ARA-290 activates the innate repair receptor (a complex of erythropoietin receptor and CD131) to initiate tissue-protective signaling pathways including JAK2-STAT3 and PI3K-Akt, which promote nerve cell survival and axonal regeneration. This mechanism addresses the underlying nerve fiber loss rather than simply blocking pain transmission like gabapentin or pregabalin, which work by reducing neurotransmitter release in pain pathways. Clinical trials demonstrate ARA-290 increases intraepidermal nerve fiber density on skin biopsy — actual structural nerve regrowth — whereas conventional analgesics provide symptom relief without affecting nerve fiber counts.

ARA-290 shows strongest evidence in patients with biopsy-confirmed small fiber neuropathy of inflammatory or immune-mediated etiology, particularly sarcoidosis-associated cases where the published trial demonstrated clearest benefit. Patients require formal diagnosis through skin punch biopsy showing reduced intraepidermal nerve fiber density (typically below 7 fibers/mm at the ankle) or corneal confocal microscopy demonstrating small fiber loss, since standard nerve conduction studies cannot detect small fiber damage. Use remains investigational without regulatory approval, requiring physician supervision and informed consent regarding the limited evidence base.

Published clinical trials used 4 mg administered subcutaneously three times weekly for 28 days in the sarcoidosis trial, and 8 mg once daily for 28 days in the diabetic neuropathy trial. Pain reduction typically becomes measurable within 4–8 weeks, while nerve fiber density changes require 8–12 weeks to manifest on repeat skin biopsy or corneal confocal microscopy. Effects persist for 4–8 weeks after treatment discontinuation, suggesting structural repair rather than transient receptor modulation. Longer treatment courses and maintenance dosing regimens are under investigation but lack published protocols.

ARA-290 is not FDA-approved for any indication and therefore carries no standard insurance coverage — patients accessing it through investigational protocols or off-label physician prescription pay out-of-pocket. Research-grade ARA-290 from verified suppliers typically costs $180–$320 per 5 mg vial depending on purity specifications and synthesis batch size. A 28-day treatment course at 4 mg three times weekly requires approximately 48 mg total (9–10 vials at typical concentrations), placing total peptide cost in the range of $1,600–$3,200 excluding physician consultation and monitoring expenses.

Clinical trials report mild injection site reactions (erythema or induration) in approximately 15% of patients as the most common adverse event. Critically, ARA-290 does not activate erythropoietic pathways at therapeutic doses — no patients in published trials developed elevated hemoglobin or polycythemia, distinguishing it from full-length erythropoietin which carries significant cardiovascular and thromboembolic risk. Long-term safety data beyond 12 weeks of treatment remains unavailable, and theoretical concerns about chronic tissue-protective receptor activation promoting tumor cell survival in patients with occult malignancy have not been systematically investigated.

ARA-290 demonstrates larger effect sizes in pain reduction and nerve fiber density improvement than alpha-lipoic acid, but with substantially higher cost and more limited safety data. German trials of alpha-lipoic acid 600 mg daily showed modest intraepidermal nerve fiber density improvement over 24 weeks in diabetic neuropathy, whereas ARA-290 produced measurable nerve density increases within 8–12 weeks in sarcoidosis patients. Alpha-lipoic acid costs approximately $15–$30 monthly with excellent long-term safety profile, making it appropriate first-line therapy for metabolic neuropathy, while ARA-290 represents escalation for inflammatory subtypes or refractory cases.

Published evidence demonstrates both prevention of ongoing damage and partial reversal of existing nerve loss — skin biopsy studies show increased intraepidermal nerve fiber density from baseline, not merely stabilization. In the sarcoidosis trial, patients showed mean increase of 1.2 fibers/mm from baseline after 28 days of treatment, indicating new nerve fiber sprouting into previously denervated epidermis. However, the degree of reversibility likely depends on how recently the nerve loss occurred — chronic denervation with complete absence of residual nerve fibers for years may lack the axonal substrate necessary for regeneration.

Lyophilized ARA-290 powder must be stored at −20°C (freezer temperature) before reconstitution to prevent degradation. Once reconstituted with bacteriostatic water, store the solution at 2–8°C (refrigerator temperature) and use within 14 days — never freeze reconstituted peptide as freeze-thaw cycles denature the conformational structure required for receptor binding. Temperature excursions above 25°C for more than 2 hours cause irreversible peptide aggregation that eliminates biological activity even if the solution appears visually unchanged. Always verify cold-chain shipping documentation upon receipt.

Definitive diagnosis requires skin punch biopsy with quantification of intraepidermal nerve fiber density (IENFD), typically taken from the distal leg at a standardized site 10 cm above the lateral malleolus. Normal IENFD at this site is approximately 13–15 fibers/mm in healthy adults; values below 7 fibers/mm confirm small fiber neuropathy. Corneal confocal microscopy provides non-invasive alternative assessment by quantifying corneal nerve fiber density, branch density, and length. Standard nerve conduction studies and EMG cannot detect small fiber damage since these tests measure only large myelinated fiber function.

Inflammatory and immune-mediated small fiber neuropathy subtypes show more consistent response than purely metabolic etiologies in published studies. The clearest evidence exists for sarcoidosis-associated small fiber neuropathy, where the randomized controlled trial demonstrated statistically significant pain reduction and nerve fiber density improvement. Patients with Sjögren’s syndrome, celiac disease, or other autoimmune conditions may respond similarly given the shared inflammatory pathology, though formal trials in these populations have not been completed. Diabetic neuropathy showed subgroup benefit only, suggesting metabolic nerve damage responds less robustly to tissue-protective signaling.

ARA-290 consists of an exact 11-amino-acid sequence — even a single amino acid deletion, substitution, or oxidation eliminates receptor binding specificity and biological activity. Peptide synthesis at 95% purity means 5% of the product consists of deletion sequences, truncated fragments, or side-chain modifications that compete for receptor binding without activating downstream signaling, functionally acting as antagonists to the active peptide. Research-grade applications require ≥98% purity verified by HPLC and mass spectrometry confirmation to ensure consistent biological effects. Lower-purity batches explain many reports of ‘ARA-290 didn’t work’ in preliminary studies.

Corneal confocal microscopy provides non-invasive quantification of small nerve fiber density that correlates strongly with skin biopsy IENFD and offers the advantage of serial monitoring without repeated tissue sampling. ARA-290 trials using this technique demonstrated significant increases in corneal nerve fiber length (mean increase of 1.8 mm/mm²) after 12 weeks of treatment. While skin biopsy remains the diagnostic gold standard, corneal imaging serves as valid surrogate endpoint for tracking treatment response over time, particularly when baseline skin biopsy has already established the diagnosis and serial biopsies would be impractical.